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The calcium-sensing receptor (CASR) is expressed in the pancreas where it might regulate 
calcium concentrations in pancreatic secretions. Two independent studies reported conflicting 
results claiming that commonly occurring missense variants of the CASR gene are risk factors for 
chronic pancreatitis (CP). Here, we attempted to replicate the association between CASR variants 
and CP. We analyzed 337 patients and 840 controls from the Hungarian National Pancreas 
Registry either by direct sequencing of exon 7 and the flanking noncoding regions or by TaqMan 
SNP genotyping assays. We identified two common missense variants, c.2956G>T (p.A986S), 
and c.2968A>G (p.R990G), three low-frequency variants, c.3031C>G (p.Q1011E), c.2610G>A 
(p.E870=) and c.*60T>A, and 8 rare variants including the novel variant c.1895G>A (p.G632D). 
When allelic or genotype distributions were considered, none of the CASR variants associated 
with CP. Subgroup analysis of nonalcoholic versus alcoholic patients revealed no disease 
association either. Our results demonstrate that common CASR variants do not modify the risk 










Chronic pancreatitis (CP) is a progressive inflammatory disorder of the pancreas, which often 
develops in the background of genetic susceptibility and/or chronic alcoholism [1]. 
Investigations into the genetic underpinning of CP led to the identification of several risk 
genes/variants that alter intrapancreatic trypsin activation, elicit digestive enzyme misfolding or 
affect ductal secretions [2-5]. The genes that alter risk in the so-called trypsin-dependent 
pathological pathway include the serine protease 1 and 2 (PRSS1, PRSS2) genes that encode 
human cationic and anionic trypsinogen, respectively, the serine protease inhibitor Kazal type 1 
(SPINK1) gene, the chymotrypsinogen C (CTRC) gene, and an inversion at the 
chymotrypsinogen B1-B2 (CTRB1-CTRB2) locus. Genetic changes associated with the 
misfolding-dependent pathological pathway encompass mutations in the carboxypeptidase A1 
(CPA1) gene, a subset of PRSS1 variants, and rare mutations and a hybrid allele of the carboxyl-
ester lipase (CEL) gene. Finally, the ductal pathway of CP risk comprises variants in genes that 
encode channels predominantly expressed in the pancreatic ductal epithelium such as CFTR, 
TRPV6 and CLDN2. CP is a multigenic disease and patients may carry multiple genetic 
alterations that modify risk. However, a genetic basis for CP is not always identified in patients, 
and the search for yet undiscovered susceptibility genes continues. 
The calcium-sensing receptor (CASR) gene emerged as a potential candidate for a CP risk gene 
when Felderbauer et al. described that subjects with familial hypocalciuric hypercalcemia (FHH) 
caused by heterozygous inactivating CASR mutations also developed CP if they carried a 
heterozygous SPINK1 p.N34S risk variant [6, 7]. Subsequently, screening of Indian patients with 
tropical pancreatitis confirmed compound heterozygosity for SPINK1 p.N34S and CASR 









with recurrent acute pancreatitis and FHH, who carried a heterozygous CASR mutation and a 
heterozygous c.194+2T>C SPINK1 variant [10]. These anecdotal observations suggested that 
CASR mutations might contribute to CP risk, particularly in carriers of pathogenic SPINK1 
variants. 
Two published studies screened larger CP cohorts for CASR mutations and identified commonly 
occurring exon 7 variants as potential risk factors. First, the Whitcomb group reported that CASR 
variant c.2968A>G (p.R990G) increased CP risk about 2-fold and an even more substantial 
effect was observed in alcoholics [11]. A follow-up study from the Férec group did not confirm 
this observation but found that the homozygous genotype of the CASR variant c.2956G>T 
(p.A986S) conferred a more than 3-fold increased risk to CP [12]. The authors also observed 
enrichment of rare variants in their patient cohort relative to controls. Given the discrepant 
results, additional replication studies are warranted. Here, we investigated the association of 
CASR variants with CP in a Hungarian cohort. 
 
METHODS 
Nomenclature. Nucleotide numbering reflects coding DNA numbering with the first nucleotide 
of the ATG translation initiation codon designated as +1 in the CASR reference sequence 
(genomic reference: NC_000003.12, , Homo sapiens chromosome 3, GRCh38.p13 primary 
assembly; mRNA reference: NM_000388.4). Amino acids are numbered starting with the 
initiator methionine of the primary translation product of CASR. 
Study subjects. De-identified genomic DNA samples were obtained from the Hungarian 
National Pancreas Registry (ethical approval: TUKEB 22254-1/2012/EKU, biobanking approval: 










all gave informed consent according to the ethical guidelines of the Declaration of Helsinki. The 
discovery cohort analyzed by direct DNA sequencing consisted of 261 patients with CP (106 
nonalcoholic and 155 alcoholic cases) and 224 controls. The expanded study cohort analyzed by 
TaqMan SNP genotyping contained additional 76 CP patients (36 nonalcoholic and 40 alcoholic 
cases) and 616 controls. In total, 337 unrelated patients with CP (mean age at recruitment 
56.4±12 years), including 142 with nonalcoholic CP and 195 with alcoholic CP, and 840 control 
subjects (mean age at recruitment 39.3±14.6 years) with no pancreatic disease were enrolled. 
Diagnosis of CP was based on the history of recurrent acute pancreatitis or recurrent abdominal 
pain typical for CP and/or pathological imaging findings consistent with CP, such as pancreatic 
calcifications, duct dilatation or irregularities, with or without exocrine pancreatic insufficiency 
or diabetes. Alcoholic CP was diagnosed when the patient’s history included alcohol 
consumption of more than 80 g/day (men) or 60 g/day (women) for at least two years. Part of 
this cohort was previously characterized for SPINK1 variants p.N34S and c.194+2T>C and the 
common PRSS1-PRSS2 haplotype [13, 14]. 
DNA sequencing. Exon 7 with the flanking intron 6 and 3' UTR regions was amplified using 3 
primer pairs; CASR-x7-amp1-FWD 5’-TAT GTA TTC CCA CCA CCA C-3’ and CASR-x7-
amp1-REV 5’-TGA AGG TGC AGA GGA AAA C-3’, CASR-x7-amp2-FWD 5’-GTG TTT 
GAG GCC AAG ATC C-3’ and CASR-x7-amp2-REV 5’-TTG CTC TTG CTG CTG ATG G-3’, 
CASR-x7-amp3-FWD 5’-ACA TCA TTC TCT TCA AGC CAT C-3’ and CASR-x7-amp3-REV 
5’-AGG AGT CTG GGG CGA TTC-3’. Polymerase chain reaction (PCR) was performed using 
0.5 U HotStarTaq DNA Polymerase (Qiagen), 0.2 mM dNTP, 0.5 μM primers, 10x PCR buffer 
(Qiagen) and 10 to 50 ng of genomic DNA template in a volume of 25 μL. The reaction started 










94°C, 30 sec annealing at 61.1°C (amplicon 1 and 2) or 53.2°C (amplicon 3), and 40 sec 
(amplicon 1 and 2) or 50 sec (amplicon 3) extension at 72°C; and finished by a final extension 
for 5 min at 72°C. PCR products were verified by 2% agarose gel electrophoresis. The PCR 
amplicons (5 µL) were treated with 1 µL FastAP Thermosensitive Alkaline Phosphatase and 0.5 
µL Exonuclease I (Thermo Fisher Scientific) for 15 min at 37°C, and the reaction was stopped 
by heating the samples to 85°C for 15 min. Sanger sequencing was performed using the forward 
(amplicon 1 and 3) and reverse (amplicon 2) PCR primers as sequencing primers. 
TaqMan SNP genotyping. TaqMan SNP genotyping assays were used to investigate the 
p.A986S and p.R990G CASR variants in the expanded study cohort (Assay ID: CASR 
rs1801725_7504853_20 and CASR rs1042636_7504854_20) using a StepOne Real-Time PCR 
system (Applied Biosystems by Life Technologies). The 20 µL reaction consisted of TaqPath 
ProAmp Master Mix (2x), TaqMan SNP genotyping assay (20x) and 10-20 ng genomic DNA 
template. The cycling conditions were as follows: 30 sec holding stage at 60°C followed by a 10 
min holding stage at 95°C; 50 cycles of 15 sec denaturation at 92°C and 1 min annealing at 
60°C; and a final 30 sec holding stage at 60°C. Allelic discrimination plots were evaluated using 
the StepOne software. To confirm the results, all homozygous samples and 4-6 heterozygous and 
wild-type samples from each plate were sequenced. 
Statistical analysis. The significance of the differences in allele frequencies and genotype 
distribution between cases and controls was assessed by Fisher’s exact test using the GraphPad 












DNA sequence analysis of exon 7 of human CASR in a discovery cohort. To investigate 
whether common CASR variants alter risk for CP, we initially sequenced exon 7 and flanking 
intron 6 and 3’ UTR regions of CASR in 261 patients with CP (106 nonalcoholic CP and 155 
alcoholic CP) and 224 controls from the Hungarian National Pancreas Registry. We identified 2 
common missense variants (allele frequency >5%), c.2956G>T (p.A986S) and c.2968A>G 
(p.R990G) and 3 low-frequency variants (allele frequency 1-5%), which included a missense 
variant c.3031C>G (p.Q1011E), a synonymous variant c.2610G>A (p.E870=) and a 3’ UTR 
variant c.*60T>A, which was in linkage disequilibrium with p.Q1011E. In addition, we found 8 
rare variants (allele frequency <1%), 7 of which were detected in one subject each (Figure 1, 
Table 1). The rare variants included 3 missense variants; the c.1895G>A (p.G632D) variant was 
detected in a CP patient, while two previously reported missense variants, c.1775A>G (p.N592S) 
and c.2405A>G (p.N802S) were present in controls. The novel p.G632D variant was found in a 
male, nonalcoholic patient who developed CP at the age of 37. He had no history of smoking, 
and carried no pathogenic SPINK1 variants. His total serum calcium level was in the normal 
range (2.39 mmol/L). The serum calcium levels were not available for the carriers of the 
p.N592S and p.N802S variants. 
In silico analysis using the “PredictSNP Consensus classifier for prediction of disease-related 
mutations” tool classified the p.G632D and p.N802S variants as potentially disease causing and 
the p.N592S variant as benign. 
When allele frequency was considered, distribution of the variants between CP patients and 
controls showed no significant differences. Genotype distribution of common missense variants 










dominant and recessive models of inheritance, but no significant differences between CP patients 
and controls were found (Table 2). In this analysis, a non-significant enrichment of the 
homozygous p.A986S variant was observed in patients (3.4%) versus controls (0.9%). However, 
we noticed a deviation from Hardy-Weinberg equilibrium (HWE) in the control population, 
probably due to the limited sample size. 
TaqMan SNP genotyping for the p.A986S and p.R990G variants in an expanded cohort. 
Since the homozygous p.A986S variant and the p.R990G variant were previously reported to 
associate with CP [11, 12], we expanded our study and investigated these two variants using 
TaqMan SNP genotyping assays in additional 76 CP patients (36 nonalcoholic and 40 alcoholic 
cases) and 616 controls. Taken the direct sequencing and genotyping results together, allele and 
genotype frequency of the common p.A986S and p.R990G variants were determined in 337 CP 
patients (142 nonalcoholic CP and 195 alcoholic CP) and 840 controls. Neither of these variants 
associated with CP (Table 3). Notably, in the combined results, there was no appreciable 
enrichment of the homozygous p.A986S variant in patients versus controls (2.7% versus 2.3%, 
respectively; OR=1.19, 95% CI 0.52-1.92, p=0.68). Subgroup analysis of nonalcoholic CP and 
alcoholic CP revealed no disease association either (Tables 4-5). 
 
DISCUSSION 
The calcium-sensing receptor is a dimeric, G-protein coupled transmembrane receptor that is 
highly expressed in the parathyroid glands and the kidneys where it regulates systemic calcium 
homoeostasis [15, 16]. An increase in serum calcium levels activates the receptor, triggering 
intracellular signaling to inhibit parathyroid hormone (PTH) secretion and calcium resorption. A 










increased calcium resorption in the kidneys. Similar to PTH regulation in the parathyroid glands, 
the expression of CASR in the mammary epithelia negatively regulates the secretion of PTH-
related peptide, which can mobilize calcium from bones for milk production. Heterozygous 
inactivating mutations in CASR cause FHH, an autosomal dominant disorder characterized by 
elevated serum calcium and decreased urinary calcium excretion [15, 17]. CASR mutations may 
also cause neonatal severe hyperparathyroidism, typically as a recessive disorder. In contrast, 
CASR mutations are rarely observed in adult-onset hyperparathyroidism and reduced expression 
of CASR in parathyroid adenomas is the likely explanation for the increased PTH secretion and 
hypercalcemia in this disease. Finally, activating mutations in CASR are associated with 
autosomal dominant hypocalcemia. 
In addition to its systemic, “calcitropic” role, CASR is expressed in several tissues where it 
contributes to local regulation of various cellular processes. In the rat pancreas, CASR was found 
in acinar, ductal and islet cells, and activation of the receptor was shown to induce ductal 
bicarbonate secretion [18]. CASR expression was also documented in all cell types of the human 
pancreas, including intrapancreatic nerves and blood vessels [19]. Furthermore, the human 
pancreatic adenocarcinoma cell line Capan-1 was shown to express functional CASR [19]. Based 
on these observations, it was suggested that CASR might regulate the calcium concentration of 
the pancreatic juice by increasing ductal fluid secretion, possibly through activating CFTR [5]. 
We note, however, that evidence for the exact role(s) of CASR in the pancreas is limited and 
animal models with pancreas-specific CASR deletion or mutation have been lacking. The 
strongest indication that CASR mutations may play a role in pancreatitis is the relatively frequent 
occurrence of pancreatitis in FHH [20]. In a small number of FHH patients, trans-heterozygosity 









associated pancreatitis is due to hypercalcemia rather than the local effects of inactivating CASR 
mutations in the pancreas. Hypercalcemia is a well-known risk factor for pancreatitis. 
Hyperparathyroidism and malignancy-associated hypercalcemia are two commonly reported 
conditions in which pancreatitis frequently occurs in association with elevated serum calcium 
levels [21-23]. Importantly, experimental studies in rats also demonstrated that hypercalcemia 
could induce pancreatitis [24-26]. SPINK1 variants represent an independent risk factor for CP, 
which often interact with other genetic and environmental risk factors to promote disease onset 
and progression. Thus, it is not surprising that some FHH patients with pancreatitis might carry 
SPINK1 mutations as well. 
Considering the role of commonly occurring CASR variants in CP risk, human genetic 
association studies yielded conflicting results (see Introduction). Therefore, in the present study, 
we examined the contribution of common exon 7 CASR variants to CP risk in a Hungarian cohort 
of nonalcoholic and alcoholic CP cases. A limitation of our analysis was the relatively small size 
of the patient cohorts. We identified 5 CASR variants with a population frequency above 1%, 
none of which showed an association with CP. No enrichment was observed when allelic or 
genotype distributions were considered or in a subgroup analysis of nonalcoholic and alcoholic 
patients. SPINK1 mutation status was not analyzed, but we note that SPINK1 variants p.N34S 
and c.194+2T>C are rare in this Hungarian CP cohort [13]. We conclude that the previously 
reported associations between common CASR variants and CP were likely spurious due to 
chance and/or multiple testing. This conclusion is in agreement with the reported functional 
properties of these variants. Thus, in transfected HEK 293 cells variants p.A986S and p.Q1011E 
behaved exactly as wild-type CASR while variant p.R990G showed slightly enhanced function 










primary hypercalciuria [27] but it seems difficult to reconcile with pancreatitis. Finally, we found 
a novel missense variant in a CP patient (p.G632D) and two previously reported rare missense 
variants in controls (p.N592S, p.N802S). Variants p.G632D and p.N802S were predicted to be 
functionally deleterious. Indeed, variant p.N802S was described as an inactivating mutation 
associated with FHH [28]. No enrichment of rare missense variants was observed in the patient 
cohort. However, our analysis was limited to exon 7 and a direct comparison with the relevant 
results of the Férec group cannot be made [12].  
Intracellular calcium signaling plays a critical role in pancreas physiology and aberrant calcium 
signaling is a hallmark of pancreatitis. Changes in extracellular calcium may have profound 
effects on calcium signaling and may directly promote activation of digestive proteases. Besides 
CASR, recent genetic studies focused on other calcium channels and receptors as well [29-32]. 
While the interesting preliminary findings with GPRC6A and STIM1 await further replication 
[29, 32], the TRPV6 gene encoding a constitutive calcium channel was convincingly identified as 
a high-impact CP risk gene [5, 30, 31]. Loss-of-function mutations in TRPV6 are strongly 
associated with CP with a large effect size. TRPV6 is expressed in both acinar and ductal cells 
and the disease-causing mechanism of TRPV6 mutations has remained unclear so far. Because 
higher expression levels were reported in the ductal epithelium, the TRPV6 gene was tentatively 
assigned to the ductal pathological pathway of CP risk [5]. One can speculate that TRPV6 might 
regulate pancreatic juice calcium concentrations in concert with CASR. A recent example for 
functional interaction between these two molecules was described in the intestinal epithelium, 
where activation of CASR in the basolateral membrane attenuates TRPV6-dependent intestinal 
calcium absorption [33]. However, in light of our present data, TRPV6 more likely functions in a 










In summary, our results demonstrate that common CASR variants do not modify the risk for CP 
and should not be considered as genetic risk factors in the clinical setting. 
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Table 1. Allele frequency of CASR variants in the discovery cohort. OR, odds ratio, CI, confidence interval. 
 
Location Nucleotide change Amino-acid change rs number Patients Controls OR 95% CI p-value 
Intron 6 c.1733-9A>G  rs190731787 1/522 0/448    
Exon 7 c.1775A>G p.N592S rs117375173 0/522 1/448    
Exon 7 c.1895G>A  p.G632D - 1/522 0/448    
Exon 7 c.1942C>A p.R648= rs104893705 1/522 0/448    
Exon 7 c.2388G>A p.K796= rs200701164 0/522 1/448    
Exon 7 c.2405A>G p.N802S rs140022350 0/522 1/448    
Exon 7 c.2610G>A p.E870= rs143738711 2/522 (0.4%) 5/448 (1.1%) 0.34 0.07-1.58 0.26 
Exon 7 c.2838G>A p.Q946= rs774889993 2/522 (0.4%) 2/448 (0.5%)    
Exon 7 c.2956G>T p.A986S rs1801725 101/522 (19.4%) 83/448 (18.5%) 1.06 0.76-1.45 0.81 
Exon 7 c.2968A>G  p.R990G rs1042636 41/522 (7.9%) 26/448 (5.8%) 1.38 0.84-2.29 0.25 
Exon 7 c.2979G>A  p.T993= rs917914806 1/522 0/448    
Exon 7 c.3031C>G  p.Q1011E rs1801726 19/522 (3.6%) 20/448 (4.5%) 0.81 0.44-1.57 0.52 
3’ UTR c.*60T>Aa  rs4677948 19/522 (3.6%) 20/448 (4.5%) 0.81 0.44-1.57 0.52 
 












Table 2. Genotype distribution of common CASR variants in the discovery cohort. Genotypes were analyzed assuming dominant (shown in 
italics) or recessive models of inheritance. OR, odds ratio, CI, confidence interval, HWE, Hardy-Weinberg equilibrium (p-value is shown). 
 
  
Location Nucleotide change Genotype Patients Controls OR 95% CI p-value HWE 
Exon 7 c.2956G>T 
GG 169/261 (64.8%) 143/224 (63.8%)     
GT 83/261 (31.8%) 79/224 (35.3%) 0.96 0.66-1.39 0.85 0.01 
TT 9/261 (3.4%) 2/224 (0.9%) 3.96 1.02-18.43 0.07  
Exon 7 c.2968A>G 
AA 220/261 (84.3%) 198/224 (88.4%)     
AG 41/261 (15.7%) 26/224 (11.6%) 1.42 0.84-2.44 0.24 0.36 
GG 0/261 (0%) 0/224 (0%)     
Exon 7 c.3031C>G 
CC 242/261 (92.7%) 205/224 (91.5%)     
CG 19/261 (7.3%) 18/224 (8%) 0.85 0.44-1.62 0.74 0.39 










Table 3. Genotype distribution and allele frequency of c.2956G>T (p.A986S) and c.2968A>G (p.R990G) variants in the expanded study 
population. Genotypes were analyzed assuming dominant (shown in italics) or recessive models of inheritance. OR, odds ratio, CI, confidence 
interval, HWE, Hardy-Weinberg equilibrium (p-value is shown). 
 
  
Location Nucleotide change Genotype Patients Controls OR 95% CI p-value HWE 
Exon 7 c.2956G>T 
GG 222/337 (65.9%) 558/840 (66.4%)     
GT 106/337 (31.4%) 263/840 (31.3%) 1.03 0.79-1.34 0.89 0.06 
TT 9/337 (2.7%) 19/840 (2.3%) 1.19 0.52-1.92 0.68  
T 124/674 (18.4%) 301/1680 (17.9%) 1.03 0.82-1.30 0.81  
Exon 7 c.2968A>G 
AA 289/337 (85.8%) 732/840 (87.2%)     
AG 48/337 (14.2%) 102/840 (12.1%) 1.13 0.78-1.62 0.57 0.25 
GG 0/337 (0%) 6/840 (0.7%)     










Table 4. Genotype distribution and allele frequency of c.2956G>T (p.A986S) and c.2968A>G (p.R990G) variants in patients with nonalcoholic 















Location Nucleotide change Genotype Patients Controls OR 95% CI p-value 
Exon 7 c.2956G>T 
GG 91/142 (64.1%) 558/840 (66.4%)    
GT 46/142 (32.4%) 263/840 (31.3%) 1.11 0.76-1.6 0.63 
TT 5/142 (3.5%) 19/840 (2.3%) 1.58 0.63-4.06 0.38 
T 56/284 (19.7%) 301/1680 (17.9%) 1.13 0.82-1.55 0.46 
Exon 7 c.2968A>G 
AA 125/142 (88%) 732/840 (87.2%)    
AG 17/142 (12%) 102/840 (12.1%) 0.92 0.53-1.58 0.89 
GG 0/142 (0%) 6/840 (0.7%)    
  










Table 5. Genotype distribution and allele frequency of c.2956G>T (p.A986S) and c.2968A>G (p.R990G) variants in patients with alcoholic 















Location Nucleotide change Genotype Patients Controls OR 95% CI p-value 
Exon 7 c.2956G>T 
GG 131/195 (67.2%) 558/840 (66.4%)    
GT 60/195 (30.8%) 263/840 (31.3%) 0.97 0.7-1.35 0.87 
TT 4/195 (2%) 19/840 (2.3%) 0.91 0.33-2.57  >0.99 
T 68/390 (17.4%) 301/1680 (17.9%) 0.97 0.72-1.29 0.88 
Exon 7 c.2968A>G 
AA 164/195 (84.1%) 732/840 (87.2%)    
AG 31/195 (15.9%) 102/840 (12.1%) 1.28 0.83-1.97 0.29 
GG 0/195 (0%) 6/840 (0.7%)    
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LEGEND TO FIGURE 
Figure 1. Snakeplot showing the calcium-sensing receptor (CASR) missense variants found in 
the Hungarian cohort. The amino acids coded by exon 7 are highlighted with light grey, rare 
missense variants p.N592S, p.G632D, and p.N802S are shown in dark gray, while common 
variants p.A986S, and p.R990G, and low-frequency variant p.Q1011E are depicted in black. The 
snakeplot was generated by GPCRdb [34]. 
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